| Literature DB >> 9592996 |
F C Spector1, E R Kern, J Palmer, R Kaiwar, T A Cha, P Brown, R R Spaete.
Abstract
Recombinant virus RAV 9395 was constructed by deleting both copies of the gamma(1)34.5 gene, and the UL55 and UL56 open reading frames from herpes simplex virus type 2 (HSV-2) strain G. The potential use of RAV 9395 as an HSV-2 vaccine was investigated by evaluating the ability of RAV 9395 to protect guinea pigs from severe disease by HSV-2(G) challenge. RAV 9395 administered intramuscularly reduced both lesion development and severity in a dose-dependent manner in guinea pigs challenged with HSV-2(G). The frequency of reactivation of RAV 9395 from explanted dorsal root ganglia was low compared with that of HSV-2(G). Immunization with RAV 9395 at doses of 1 x 10(5) pfu and above generally precluded the establishment of latency by the challenge virus. The results presented in this report lend support for the development of genetically engineered live HSV vaccines.Entities:
Mesh：
Substances：
Year: 1998 PMID： 9592996 DOI： 10.1086/515278
Source DB: PubMed Journal: J Infect Dis ISSN： 0022-1899 Impact factor: 5.226